| Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer … F Magro, P Gionchetti, R Eliakim, S Ardizzone, A Armuzzi, ... Journal of Crohn's and Colitis 11 (6), 649-670, 2017 | 1677 | 2017 |
| The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease M Harbord, V Annese, SR Vavricka, M Allez, M Barreiro-de Acosta, ... Journal of Crohn's and Colitis 10 (3), 239-254, 2016 | 805 | 2016 |
| 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 2: surgical management and special situations P Gionchetti, A Dignass, S Danese, FJ Magro Dias, G Rogler, PL Lakatos, ... Journal of Crohn's and Colitis 11 (2), 135-149, 2017 | 779 | 2017 |
| European Crohn’s and Colitis Organisation [ECCO]. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis … F Magro, P Gionchetti, R Eliakim, S Ardizzone, A Armuzzi, ... J Crohns Colitis 11 (6), 649-670, 2017 | 366 | 2017 |
| Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients M Chaparro, I Ordás, E Cabré, V Garcia-Sanchez, G Bastida, M Peñalva, ... Inflammatory bowel diseases 19 (7), 1404-1410, 2013 | 323 | 2013 |
| Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease MJ Casanova, M Chaparro, E Domenech, M Barreiro-de Acosta, ... Official journal of the American College of Gastroenterology| ACG 108 (3 …, 2013 | 263 | 2013 |
| Evaluation of the risk of relapse in ulcerative colitis according to the degree of mucosal healing (Mayo 0 vs 1): a longitudinal cohort study M Barreiro-de Acosta, N Vallejo, D de la Iglesia, L Uribarri, I Bastón, ... Journal of Crohn's and Colitis 10 (1), 13-19, 2016 | 206 | 2016 |
| Prevalence of malnutrition and nutritional characteristics of patients with inflammatory bowel disease MJ Casanova, M Chaparro, B Molina, O Merino, R Batanero, ... Journal of Crohn's and Colitis 11 (12), 1430-1439, 2017 | 188 | 2017 |
| European Crohn’s and Colitis Organisation M Harbord, V Annese, SR Vavricka, M Allez, M Barreiro-de Acosta, ... The first European evidence-based consensus on extra-intestinal …, 2016 | 188 | 2016 |
| Psychological factors are associated with changes in the health-related quality of life in inflammatory bowel disease M Iglesias-Rey, M Barreiro-de Acosta, F Caamaño-Isorna, IV Rodríguez, ... Inflammatory bowel diseases 20 (1), 92-102, 2014 | 170 | 2014 |
| Infliximab salvage therapy after failure of ciclosporin in corticosteroid‐refractory ulcerative colitis: a multicentre study M Chaparro, P Burgueño, E Iglesias, J Panés, F Muñoz, G Bastida, ... Alimentary pharmacology & therapeutics 35 (2), 275-283, 2012 | 124 | 2012 |
| Emigration to western industrialized countries: A risk factor for developing inflammatory bowel disease M Barreiro-de Acosta, A Alvarez Castro, R Souto, M Iglesias, A Lorenzo, ... Journal of Crohn's and Colitis 5 (6), 566-569, 2011 | 119 | 2011 |
| Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab C Taxonera, J Estelles, I Fernández‐Blanco, O Merino, I Marín‐Jiménez, ... Alimentary pharmacology & therapeutics 33 (3), 340-348, 2011 | 118 | 2011 |
| Evolution after anti-TNF discontinuation in patients with inflammatory bowel disease: a multicenter long-term follow-up study MJ Casanova, M Chaparro, V García-Sánchez, O Nantes, E Leo, ... Official journal of the American College of Gastroenterology| ACG 112 (1 …, 2017 | 114 | 2017 |
| European Crohn’s and Colitis Organisation topical review on complementary medicine and psychotherapy in inflammatory bowel disease J Torres, P Ellul, J Langhorst, A Mikocka-Walus, M Barreiro-de Acosta, ... Journal of Crohn's and Colitis 13 (6), 673-685e, 2019 | 111 | 2019 |
| Clinical outcomes of golimumab as first, second or third anti-TNF agent in patients with moderate-to-severe ulcerative colitis C Taxonera, C Rodriguez, F Bertoletti, L Menchen, J Arribas, M Sierra, ... Inflammatory bowel diseases 23 (8), 1394-1402, 2017 | 92 | 2017 |
| Short and long‐term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry M Chaparro, A Garre, E Ricart, M Iborra, F Mesonero, I Vera, S Riestra, ... Alimentary pharmacology & therapeutics 48 (8), 839-851, 2018 | 88 | 2018 |
| Efficacy of adalimumab rescue therapy in patients with chronic refractory pouchitis previously treated with infliximab: a case series M Barreiro-de Acosta, O García-Bosch, J Gordillo, M Mañosa, L Menchén, ... European journal of gastroenterology & hepatology 24 (7), 756-758, 2012 | 85 | 2012 |
| Fecal calprotectin as predictor of relapse in patients with inflammatory bowel disease under maintenance infliximab therapy R Ferreiro-Iglesias, M Barreiro-de Acosta, M Otero Santiago, ... Journal of clinical gastroenterology 50 (2), 147-151, 2016 | 79 | 2016 |
| Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease F Argüelles-Arias, L Castro-Laria, T Lobatón, M Aguas-Peris, ... Digestive diseases and sciences 58 (10), 2949-2954, 2013 | 79 | 2013 |
Luisa Fernanda Mogollón FrancoEstudiante de trabajo socialVerified email at unicolmayor.edu.co
